Zacks Research Has Optimistic Outlook of PBYI Q3 Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for shares of Puma Biotechnology in a research note issued to investors on Thursday, October 17th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn $0.24 per share for the quarter, up from their previous forecast of $0.22. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.25 per share.

PBYI has been the topic of several other research reports. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, August 2nd.

Puma Biotechnology Trading Up 1.8 %

PBYI opened at $2.88 on Friday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.23 and a current ratio of 1.32. The stock’s 50 day moving average price is $2.64 and its 200-day moving average price is $3.60. Puma Biotechnology has a one year low of $2.13 and a one year high of $7.73. The stock has a market cap of $141.26 million, a price-to-earnings ratio of 15.16 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $43.99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. During the same quarter in the prior year, the firm earned $0.05 earnings per share.

Hedge Funds Weigh In On Puma Biotechnology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PBYI. American Century Companies Inc. boosted its stake in Puma Biotechnology by 98.5% during the 2nd quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock worth $2,409,000 after purchasing an additional 366,653 shares during the last quarter. Affinity Asset Advisors LLC purchased a new position in shares of Puma Biotechnology during the 2nd quarter worth approximately $815,000. Frazier Life Sciences Management L.P. raised its holdings in shares of Puma Biotechnology by 8.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after buying an additional 246,264 shares during the period. Great Point Partners LLC lifted its position in shares of Puma Biotechnology by 10.6% during the second quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 142,916 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Puma Biotechnology by 63.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 308,997 shares of the biopharmaceutical company’s stock worth $1,007,000 after buying an additional 120,104 shares in the last quarter. 61.29% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Michael Patrick Miller sold 23,358 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $3.49, for a total transaction of $81,519.42. Following the sale, the director now directly owns 47,000 shares of the company’s stock, valued at approximately $164,030. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 23.70% of the stock is owned by insiders.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.